Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.
2.

Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.

Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.

J Manag Care Pharm. 2011 Oct;17(8):621-43.

3.

Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.

Gomez-Veiga F, Ponce-Reixa J, Martinez-Breijo S, Planas J, Morote J.

Actas Urol Esp. 2013 May;37(5):292-304. doi: 10.1016/j.acuro.2012.09.001. Epub 2012 Dec 13. Review. English, Spanish.

PMID:
23246105
4.

Bisphosphonates and other bone agents for breast cancer.

Wong MH, Stockler MR, Pavlakis N.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD003474. doi: 10.1002/14651858.CD003474.pub3. Review.

PMID:
22336790
5.

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.

Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, Chi KN, Balakumaran A, Wei R, Wang H, Braun A, Fizazi K.

Ann Oncol. 2015 Feb;26(2):368-74. doi: 10.1093/annonc/mdu519. Epub 2014 Nov 25. Erratum in: Ann Oncol. 2015 Jun;26(6):1274.

6.

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K.

J Med Econ. 2012;15(4):712-23. doi: 10.3111/13696998.2012.675380. Epub 2012 Mar 27.

PMID:
22409231
7.

Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours.

Ford J, Cummins E, Sharma P, Elders A, Stewart F, Johnston R, Royle P, Jones R, Mulatero C, Todd R, Mowatt G.

Health Technol Assess. 2013 Jul;17(29):1-386. doi: 10.3310/hta17290. Review.

8.

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A.

J Clin Oncol. 2010 Dec 10;28(35):5132-9. doi: 10.1200/JCO.2010.29.7101. Epub 2010 Nov 8.

PMID:
21060033
9.
10.

Future of bisphosphonates and denosumab for men with advanced prostate cancer.

Iranikhah M, Stricker S, Freeman MK.

Cancer Manag Res. 2014 May 3;6:217-24. doi: 10.2147/CMAR.S40151. eCollection 2014. Review.

11.

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer.

El-Amm J, Aragon-Ching JB.

Clin Med Insights Oncol. 2016 Mar 23;10(Suppl 1):11-9. doi: 10.4137/CMO.S30751. eCollection 2016. Review.

12.

Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience.

Hegemann M, Bedke J, Stenzl A, Todenhöfer T.

Ther Adv Urol. 2017 Feb 6;9(3-4):81-88. doi: 10.1177/1756287216686018. eCollection 2017 Mar-Apr. Review.

13.

A comprehensive review of denosumab for bone metastasis in patients with solid tumors.

Gül G, Sendur MA, Aksoy S, Sever AR, Altundag K.

Curr Med Res Opin. 2016;32(1):133-45. doi: 10.1185/03007995.2015.1105795. Epub 2015 Nov 25. Review.

PMID:
26451465
14.

Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasis.

Wei J, Wang Z, Makarov D, Li X.

Am J Clin Exp Urol. 2013 Dec 25;1(1):30-8. eCollection 2013. Review.

15.

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C.

Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.

16.

Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer?

Saylor PJ, Michaelson MD.

Oncologist. 2012;17(2):288-90. doi: 10.1634/theoncologist.2011-0433. Epub 2012 Jan 20.

17.

Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.

Gartrell BA, Coleman RE, Fizazi K, Miller K, Saad F, Sternberg CN, Galsky MD.

Eur Urol. 2014 Feb;65(2):278-86. doi: 10.1016/j.eururo.2013.05.015. Epub 2013 May 13. Review.

18.

Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.

Saad F, Segal S, Eastham J.

Eur Urol. 2014 Jan;65(1):146-53. doi: 10.1016/j.eururo.2012.05.007. Epub 2012 May 12.

PMID:
22633317
19.

Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.

El-Amm J, Freeman A, Patel N, Aragon-Ching JB.

Prostate Cancer. 2013;2013:210686. doi: 10.1155/2013/210686. Epub 2013 Aug 28. Review.

20.

Bone matters in lung cancer.

Brodowicz T, O'Byrne K, Manegold C.

Ann Oncol. 2012 Sep;23(9):2215-22. doi: 10.1093/annonc/mds009. Epub 2012 Feb 22. Review.

Supplemental Content

Support Center